Kiromic BioPharma is an artificial intelligence driven, end-to-end Chimeric Antigen Receptor T cell and gene therapy company. Co.'s Procel, Isocel, and Deltacel platforms consist of allogeneic cell therapy product candidates that are in the preclinical development stage. Co.'s Procel product candidate consists of engineered GDTs that target PD-L1. Co.'s Isocel product candidate consists of engineered Gamma Delta T cells that target Mesothelin Isoform 2 positive tumors. Co.'s Deltacel product candidate consists of non-engineered GDTs that have been expanded and activated ex- vivo through a process, and are used to treat solid tumors regardless of the specific tumor antigen expression. The KRBP average annual return since 2020 is shown above.
The Average Annual Return on the KRBP average annual return since 2020 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether KRBP average annual return since 2020 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the KRBP average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|